Barry LE, Crealey GE, Cockwell P, Elliman SJ, et al. Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis. PLoS One 2022;17:e0274136.
PMID: 36331936